查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
大腸癌檢驗市場 - 全球及各地區分析:各技術，各樣品類型，各終端用戶，各國 - 分析與預測(2023年～2033年)
市場調查報告書
商品編碼
1289015

大腸癌檢驗市場 - 全球及各地區分析:各技術，各樣品類型，各終端用戶，各國 - 分析與預測(2023年～2033年)

Colorectal Cancer Screening and Diagnostic Market - A Global and Regional Analysis: Focus on Type, End User, and Country Analysis - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 171 Pages | 商品交期: 1-5個工作天內

價格

全球大腸癌檢驗的市場規模，預計從2022年的19億3,000萬美元到2033年達到97億3,000萬美元，從預測期間的2023年到2033年以15.94％的年複合成長率擴大。

全球大腸癌檢驗市場成長，是由於大腸癌的罹患率上升和對醫療保健的經濟負擔增加，基因學和分子診斷的進步，大腸癌的非侵入性檢驗的需求增加。

本報告提供全球大腸癌檢驗市場相關調查，市場概要，以及各技術，各樣品類型，各終端用戶，各國的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場

  • 全球市場的展望
  • 產業的展望

第2章 全球大腸癌檢驗市場(各技術)

  • 機會的評估
  • 成長佔有率矩陣
  • 大便潛血試驗(FOBT)及航班免疫化學檢查(FIT)
  • 分子檢驗

第3章 全球大腸癌檢驗市場(各樣品類型)

  • 機會的評估
  • 成長佔有率矩陣
  • 航班樣品
  • 血液樣品
  • 其他

第4章 全球大腸癌檢驗市場(各地區)

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第5章 市場-競爭基準和企業簡介

  • 競爭基準
    • 主要的策略與展開
  • 企業簡介
    • Clinical Genomics Technologies Pty Ltd.
    • Danaher Corporation
    • DiaCarta, Inc.
    • Eiken Chemical Co., Ltd.
    • Epigenomics AG
    • Exact Sciences Corporation
    • Freenome Holdings, Inc.
    • Guardant Health, Inc.
    • Lepu Medical Technology (Beijing) Co., Ltd.
    • Mainz Biomed NV
    • New Horizon Health
    • Novigenix SA
    • Prenetics Global Limited
    • Quest Diagnostics
    • QuidelOrtho Corporation
Product Code: BHP1355SA

“Global Colorectal Cancer Screening and Diagnostic Market to Reach $28.52 Billion by 2033.”

Industry Overview

The global colorectal cancer screening and diagnostic market was valued at $15.28 billion in 2022 and is expected to reach $28.52 billion by 2033, growing at a CAGR of 5.93% during the forecast period 2023-2033. The colorectal cancer screening and diagnostic market is driven by several factors, including the rising incidence of colorectal cancer and increasing financial burden on healthcare, advances in genomics and molecular diagnostics, and growing demand for colorectal cancer testing.

Market Introduction

The global colorectal cancer screening and diagnostic market is witnessing significant growth due to rising awareness about early detection of colorectal cancer. Various screening and diagnostic methods, including colonoscopy, biomarker testing are being utilized to detect and monitor colorectal cancer in its early stages. Technological advancements and collaborations between stakeholders are driving market expansion. The focus is on improving screening accuracy, sensitivity, and specificity to enhance patient outcomes. With increasing incidence rates and ongoing research, the market is all set to witness significant growth, leading to improved patient care and reduced mortality rates.

Industrial Impact

The global incidence of colorectal cancer is rising. It is the third most common cancer worldwide, resulting in a significant financial burden on healthcare systems. Screening for colorectal cancer is crucial for early detection and improved patient outcomes, but access to screening programs and resources is limited in many regions. Advances in genomics and molecular diagnostics have revolutionized colorectal cancer detection, diagnosis, and treatment. Genetic testing can help identify individuals at high risk and guide treatment decisions based on specific gene mutations. Non-invasive testing methods, such as liquid biopsy, offer less invasive and more accessible options for screening, leading to increased patient participation and early detection.

There is a growing demand for colorectal cancer screening due to factors such as rise colorectal cancer incidence and rising patient awareness in developing economies. Colonoscopies currently is considered gold standard for colorectal cancer screening and diagnostics. Moreover, Non-invasive tests have further improved the screening rates around the world mainly owing to it being cost-effective, accessible, and preferred by patients. This trend is expected to continue, driving the growth of the colorectal cancer screening and diagnostic market. Early detection of colorectal cancer leads to improved survival rates and reduces treatment costs. Regular population-wide screening programs, especially in emerging markets, are being implemented to increase early detection and treatment. These programs create a favorable market environment for screening technologies and diagnostic kits.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the global colorectal cancer screening and diagnostic market. Research activities for colorectal cancer were halted as resources were redirected to COVID-19 research. Screening programs were delayed or canceled, and colonoscopies, the gold standard for screening, were postponed, potentially leading to missed or late-stage cancer diagnoses. Colorectal cancer screening saw a drastic reduction worldwide, ranging from 28% to 100%. However, the pandemic led to increased adoption of at-home testing methods and a rise in patient awareness of non-invasive screening. As the situation normalizes, the market is expected to recover, with increased utilization of non-invasive screening tests.

Market Segmentation:

Segmentation 1: by Type

  • Screening
  • Diagnostic

Based on type, the colorectal cancer screening and diagnostic market is led by screening tests, which held a 84.80% share in 2022. Stool-based tests have shown promising results in detecting colorectal cancer and precancerous lesions, making it an effective tool for early detection. The stool-based tests are an innovative diagnostic tool that analyzes stool samples to detect specific DNA markers associated with colorectal cancer. Companies such as Exact Sciences Corporation and MAINZ BIOMED N.V. provide products in this segment. The fecal occult blood test (FOBT) and fecal immunochemical test (FIT) segments of the colorectal cancer screening and diagnostic market are expected to experience significant growth. These tests examine stool samples for undetectable blood and are widely used for colorectal cancer screening, particularly in developed countries. Early detection is crucial as colon cancer is a common cancer globally. The fecal occult blood test detects the presence of blood, indicating the need for further testing to determine the cause. FIT has replaced FOBT due to its improved specificity, sensitivity, and lower costs.

Segmentation 2: by Region

  • North America - U.S. and Canada
  • Europe - Germany, France, Italy, U.K., Spain, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-South America
  • Middle East and Africa - U.A.E., South Africa, and Rest-of-Middle East and Africa

In the market, North America held the largest share of 46.83% in 2022, followed by Europe at 26.17%. Additionally, Asia-Pacific is anticipated to grow considerably at high growth, registering a CAGR of 7.03% during the forecast period 2023-2033.

Recent Developments in the Colorectal Cancer Screening and Diagnostic Market

  • In May 2023, Olympus Corporation launched the CF-HQ1100DL/I colonovideoscope, a specialized device designed for examining the lower digestive tract, including the anus, rectum, sigmoid colon, colon, and ileocecal valve, thereby expanding its product portfolio in the field of colorectal cancer screening and diagnosis.
  • In May 2022, ColoClear, a non-invasive stool DNA test to identify colon cancer, was launched by New Horizon Health in collaboration with Prenetics in Hong Kong.
  • In April 2023, Mainz Biomed NV announced that three German companies have chosen to include ColoAlert, the company's at-home screening test for colorectal cancer (CRC), in their corporate health programs. ColoAlert is a highly effective and user-friendly screening test that enables the early detection of CRC.
  • In October 2020, Exact Sciences Corporation announced an extension and amendment of its Cologuard Promotion Agreement with Pfizer Inc. As per the agreement, Pfizer would continue to provide marketing and relevant assistance for Cologuard and collaborate with Exact Sciences Corporation to raise awareness about Cologuard among patients, healthcare providers, and healthcare systems.

Demand - Drivers and Limitations

Market Demand Drivers:

  • Rising Incidence of Colorectal Cancer and Increasing Financial Burden on Healthcare: Colorectal cancer is becoming increasingly common in many parts of the world, including low- and middle-income countries. According to an article published by the World Health Organization (WHO) in 2022, colorectal cancer is the third most common cancer worldwide, with an estimated 1.93 million new cases and 916,000 deaths in 2020 alone.
  • Advances in Genomics and Molecular Diagnostics: Advances in genomics and molecular diagnostics have resulted in significant improvements in colorectal cancer detection, diagnosis, and treatment. These advancements have been enabled by the development of new technologies that allow for the analysis of genetic and molecular changes in cancer cells.
  • Growing Demand for Colorectal Cancer Testing: Non-invasive testing has become increasingly important in colorectal cancer screening, as it offers several advantages and is generally less expensive and less invasive than colonoscopy, making it more accessible to patients and potentially increasing screening rates. Additionally, non-invasive tests can be used more frequently, allowing for more frequent screening and potentially earlier detection of colorectal cancer.
  • Early Cancer Detection Enabling Reduced Treatment Cost: Early cancer detection significantly improves survival rates and treatment effectiveness. However, a science journal paper reveals that 50% of cancers are diagnosed at advanced stages. Screening is advantageous as it identifies cancer risks in healthy individuals before symptoms arise. Regular screening, especially for fast-growing and symptomless cancers, such as lung cancer, can greatly enhance survival rates. Implementing constant screening programs tailored to specific cancers is essential for early detection and better outcomes.

Market Challenges:

  • Limited Sensitivity of FIT/FOB Testing Kits: While non-invasive testing techniques for colorectal cancer, such as fecal immunochemical tests (FITs) and stool DNA tests, have shown promise, they do have some limitations. One of the major limitations is their limited sensitivity, meaning they may not detect all cases of colorectal cancer, particularly in the early stages. This can result in false negatives and delayed diagnosis, which can impact patient outcomes.
  • Challenges with Sample Collection: The difficulties in sample collection and patient compliance may have an impact on the growth of the market for colorectal cancer screening. Companies are developing new sample collection methods with the goal of improving patient compliance and test result accuracy. At-home testing kits such as Cologuard, ColoClear, and ColoAlert are some examples of simple-to-use and less-invasive testing methods.

Market Opportunities:

  • Expansion of Screening Programs: Population-wide screening programs are proving to be a lucrative opportunity for the colorectal cancer screening and diagnostic market by leading to an increased number of individuals being screened for colorectal cancer, leading to early detection and treatment of the disease. By improving access to screening, these programs can also reduce healthcare costs and also improve patient outcomes associated with more advanced stages of the disease resulting in a strong interest in these testing methodologies by various government and NGO screening programs.
  • Emerging Markets Proposing Significant Untapped Potential: The growing number of cases and increasing awareness of colorectal cancer are driving factors that are contributing to market growth in emerging markets. As per research published in 2021, titled "Global Colorectal Cancer Burden in 2020 and Projections to 2040," in translational oncology in Asia, colorectal cancer is the third most common cancer and is on the rise due to changing lifestyles and aging populations. China alone accounts for over 500,000 new cases and over 280,000 deaths annually, making it the highest contributor to the colorectal cancer burden in Asia. Japan also records a substantial number of deaths from colorectal cancer. These statistics highlight the significant market opportunity for colorectal cancer screening technologies in these regions.

How can this report add value to an organization?

  • Product/Innovation Strategy: The product segment helps the reader understand the different types of colorectal cancer screening and diagnostic methodologies globally. Moreover, the study provides the reader with a detailed understanding of the colorectal cancer screening and diagnostic market by end-user application (hospitals and clinics, clinical laboratories, and other end users), type (blood-based tests, stool-based tests, colonoscope, biomarker test, and other test types), and region (North America, Europe, Asia-Pacific, Latin America and Middle East and Africa).
  • Growth/Marketing Strategy: The colorectal cancer screening and diagnostic market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and new product launches. The favored strategy for the companies has been partnerships and collaborations to strengthen their position in the colorectal cancer screening and diagnostic market. For instance, in March 2023, Mainz Biomed NV announced a new partnership with Dr. Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert.
  • Competitive Strategy: Key players in the colorectal cancer screening and diagnostic market analyzed and profiled in the study involve major colorectal cancer screening kit manufacturers (stool DNA test, FIT/FOB tests), biomarker testing kit manufacturers, sigmoidoscope, and colonoscope manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the colorectal cancer screening and diagnostic market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations are expected to aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The top segment players who are leading include screening test manufacturers which includes colonoscopy and stool-based tests, which captured around 84.80% of the market in 2022. Players dealing in diagnostics, such as biomarker tests, accounted for approximately 15.20% of the market in the year 2022.

Key Companies Profiled:

  • Clinical Genomics Technologies Pty Ltd.
  • Danaher Corporation
  • DiaCarta, Inc.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Freenome Holdings, Inc.
  • Guardant Health, Inc.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Mainz Biomed NV
  • New Horizon Health
  • Novigenix SA
  • Prenetics Global Limited
  • FUJIFILM Holdings Corporation
  • Olympus Corporation
  • HOYA Corporation
  • QuidelOrtho Corporation

Table of Contents

1 Markets

  • 1.1 Global Market Outlook
    • 1.1.1 Market Overview
    • 1.1.2 Product Definition
    • 1.1.3 Inclusion and Exclusion Criteria
    • 1.1.4 Key Findings
  • 1.2 Industry Outlook
    • 1.2.1 Regulatory Framework
      • 1.2.1.1 Regulatory Framework in the U.S.
      • 1.2.1.2 Regulatory Framework in Europe
      • 1.2.1.3 Regulatory Framework in Asia-Pacific
        • 1.2.1.3.1 China
        • 1.2.1.3.2 Japan
        • 1.2.1.3.3 India
      • 1.2.1.4 Regulatory Framework in Latin America
    • 1.2.2 Reimbursement Scenario
      • 1.2.2.1 Fecal Immunochemical Testing/Fecal Occult Blood Testing
      • 1.2.2.2 Molecular Testing
    • 1.2.3 Patent Analysis
      • 1.2.3.1 Patent Filing Trend (by Country)
      • 1.2.3.2 Patent Filing Trend (by Year)
    • 1.2.4 Key Trends
      • 1.2.4.1 Rise of At-Home Colorectal Cancer Screening
      • 1.2.4.2 Multimodal Approaches to Colorectal Cancer Screening
      • 1.2.4.3 Use of Gut Microbiota in Colorectal Cancer Diagnosis
    • 1.2.5 COVID-19 Impact
      • 1.2.5.1 Impact of COVID-19 on Colorectal Cancer Screening and Diagnostic Market
      • 1.2.5.2 Pre-COVID-19 Phase
      • 1.2.5.3 During-COVID-19 Phase
      • 1.2.5.4 Post-COVID-19 Phase
    • 1.2.6 Product Landscape
    • 1.2.7 Product Pipeline
    • 1.2.8 Business Dynamics
      • 1.2.8.1 Impact Analysis
      • 1.2.8.2 Business Drivers
        • 1.2.8.2.1 Rising Incidence of Colorectal Cancer and Increasing Financial Burden on Healthcare
        • 1.2.8.2.2 Advances in Genomics and Molecular Diagnostics
        • 1.2.8.2.3 Growing Demand for Colorectal Cancer Testing
        • 1.2.8.2.4 Earlier Cancer Detection Enabling Reduced Treatment Cost
      • 1.2.8.3 Business Restraints
        • 1.2.8.3.1 Limited Sensitivity of FIT/FOBt Testing Kits
        • 1.2.8.3.2 Challenges with Sample Collection
      • 1.2.8.4 Business Opportunities
        • 1.2.8.4.1 Expansion of Screening Programs
        • 1.2.8.4.2 Emerging Markets Proposing Significant Untapped Potential

2 Global Colorectal Cancer Screening and Diagnostic Market (by Type)

  • 2.1 Opportunity Assessment
  • 2.2 Growth-Share Matrix
  • 2.3 Screening
    • 2.3.1 Stool-Based Test
      • 2.3.1.1 Fecal Occult Blood Test (FOBT) and Fecal Immunochemical Test (FIT)
      • 2.3.1.2 Stool DNA Test
    • 2.3.2 Colonoscopy and Sigmoidoscopy
    • 2.3.3 Other Screening Test
  • 2.4 Diagnostic
    • 2.4.1 Biomarker Test
    • 2.4.2 Colonoscopy

3 Global Colorectal Cancer Screening and Diagnostic Market (by End User)

  • 3.1 Opportunity Assessment
  • 3.2 Growth-Share Matrix
  • 3.3 Hospitals and Clinics
  • 3.4 Clinical Laboratories
  • 3.5 Other End Users

4 Global Colorectal Cancer Screening and Diagnostic Market (by Region)

  • 4.1 North America
    • 4.1.1 Key Findings
    • 4.1.2 Market Dynamics
      • 4.1.2.1 Impact Analysis
    • 4.1.3 Market Sizing and Forecast
      • 4.1.3.1 North America Colorectal Cancer Screening and Diagnostic Market (by End User)
      • 4.1.3.2 North America Colorectal Cancer Screening and Diagnostic Market (by Product)
      • 4.1.3.3 North America Colorectal Cancer Screening and Diagnostic Market (by Country)
        • 4.1.3.3.1 U.S.
        • 4.1.3.3.2 Canada
  • 4.2 Europe
    • 4.2.1 Key Findings
    • 4.2.2 Market Dynamics
      • 4.2.2.1 Impact Analysis
    • 4.2.3 Market Sizing and Forecast
      • 4.2.3.1 Europe Colorectal Cancer Screening and Diagnostic Market (by End User)
      • 4.2.3.2 Europe Colorectal Cancer Screening and Diagnostic Market (by Product)
      • 4.2.3.3 Europe Colorectal Cancer Screening and Diagnostic Market (by Country)
        • 4.2.3.3.1 Germany
        • 4.2.3.3.2 U.K.
        • 4.2.3.3.3 France
        • 4.2.3.3.4 Spain
        • 4.2.3.3.5 Italy
        • 4.2.3.3.6 Rest-of-Europe
  • 4.3 Asia-Pacific
    • 4.3.1 Key Findings
    • 4.3.2 Market Dynamics
      • 4.3.2.1 Impact Analysis
    • 4.3.3 Market Sizing and Forecast
      • 4.3.3.1 Asia-Pacific Colorectal Cancer Screening and Diagnostic Market (by End User)
      • 4.3.3.2 Asia-Pacific Colorectal Cancer Screening and Diagnostic Market (by Product)
      • 4.3.3.3 Asia-Pacific Colorectal Cancer Screening and Diagnostic Market (by Country)
        • 4.3.3.3.1 China
        • 4.3.3.3.2 Japan
        • 4.3.3.3.3 India
        • 4.3.3.3.4 South Korea
        • 4.3.3.3.5 Australia
        • 4.3.3.3.6 Rest-of-Asia-Pacific
  • 4.4 Latin America
    • 4.4.1 Key Findings
    • 4.4.2 Market Dynamics
      • 4.4.2.1 Impact Analysis
    • 4.4.3 Market Sizing and Forecast
      • 4.4.3.1 Latin America Colorectal Cancer Screening and Diagnostic Market (by End User)
      • 4.4.3.2 Latin America Colorectal Cancer Screening and Diagnostic Market (by Product)
      • 4.4.3.3 Latin America Colorectal Cancer Screening and Diagnostic Market (by Country)
        • 4.4.3.3.1 Brazil
        • 4.4.3.3.2 Mexico
        • 4.4.3.3.3 Rest-of-Latin-America
  • 4.5 Middle East and Africa
    • 4.5.1 Key Findings
    • 4.5.2 Market Dynamics
      • 4.5.2.1 Impact Analysis
    • 4.5.3 Market Sizing and Forecast
      • 4.5.3.1 Middle East and Africa Colorectal Cancer Screening and Diagnostic Market (by End User)
      • 4.5.3.2 Middle East and Africa Colorectal Cancer Screening and Diagnostic Market (by Product)
      • 4.5.3.3 Middle East and Africa Colorectal Cancer Screening and Diagnostic Market (by Country)
        • 4.5.3.3.1 U.A.E.
        • 4.5.3.3.2 South Africa
        • 4.5.3.3.3 Rest-of-Middle East and Africa

5 Markets - Competitive Benchmarking & Company Profiles

  • 5.1 Competitive Benchmarking
    • 5.1.1 Key Strategies and Developments
      • 5.1.1.1 Funding Activities
      • 5.1.1.2 New Offerings
      • 5.1.1.3 Business Expansion
      • 5.1.1.4 Mergers and Acquisitions
      • 5.1.1.5 Partnerships and Collaborations
  • 5.2 Company Profile
    • 5.2.1 Clinical Genomics Technologies Pty Ltd.
      • 5.2.1.1 Company Overview
      • 5.2.1.2 Role of Clinical Genomics Technologies Pty Ltd. in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.1.3 Recent Developments
      • 5.2.1.4 Analyst Perspective
    • 5.2.2 Danaher Corporation
      • 5.2.2.1 Company Overview
      • 5.2.2.2 Role of Danaher Corporation in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.2.3 Financials
      • 5.2.2.4 Analyst Perspective
    • 5.2.3 DiaCarta, Inc.
      • 5.2.3.1 Company Overview
      • 5.2.3.2 Role of DiaCarta, Inc. in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.3.3 Recent Developments
      • 5.2.3.4 Analyst Perspective
    • 5.2.4 Eiken Chemical Co., Ltd.
      • 5.2.4.1 Company Overview
      • 5.2.4.2 Role of Eiken Chemical Co., Ltd. in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.4.3 Financials
      • 5.2.4.4 Recent Developments
      • 5.2.4.5 Analyst Perspective
    • 5.2.5 Epigenomics AG
      • 5.2.5.1 Company Overview
      • 5.2.5.2 Role of Epigenomics AG in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.5.3 Financials
      • 5.2.5.4 Recent Developments
      • 5.2.5.5 Analyst Perspective
    • 5.2.6 Exact Sciences Corporation
      • 5.2.6.1 Company Overview
      • 5.2.6.2 Role of Exact Sciences Corporation in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.6.3 Financials
      • 5.2.6.4 Recent Developments
      • 5.2.6.5 Analyst Perception
    • 5.2.7 Freenome Holdings, Inc.
      • 5.2.7.1 Company Overview
      • 5.2.7.2 Role of Freenome Holdings, Inc. in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.7.3 Recent Developments
      • 5.2.7.4 Analyst Perspective
    • 5.2.8 Guardant Health, Inc.
      • 5.2.8.1 Company Overview
      • 5.2.8.2 Role of Guardant Health, Inc. in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.8.3 Financials
      • 5.2.8.4 Recent Developments
      • 5.2.8.5 Analyst Perspective
    • 5.2.9 Lepu Medical Technology (Beijing) Co., Ltd.
      • 5.2.9.1 Company Overview
      • 5.2.9.2 Role of Lepu Medical Technology (Beijing) Co., Ltd. in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.9.3 Financials
      • 5.2.9.4 Analyst Perspective
    • 5.2.10 Mainz Biomed NV
      • 5.2.10.1 Company Overview
      • 5.2.10.2 Role of Mainz Biomed NV in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.10.3 Financials
      • 5.2.10.4 Recent Developments
      • 5.2.10.5 Analyst Perspective
    • 5.2.11 New Horizon Health
      • 5.2.11.1 Company Overview
      • 5.2.11.2 Role of New Horizon Health in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.11.3 Financials
      • 5.2.11.4 Recent Developments
      • 5.2.11.5 Analyst Perspective
    • 5.2.12 Novigenix SA
      • 5.2.12.1 Company Overview
      • 5.2.12.2 Role of Novigenix SA in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.12.3 Recent Developments
      • 5.2.12.4 Analyst Perspective
    • 5.2.13 Prenetics Global Limited
      • 5.2.13.1 Company Overview
      • 5.2.13.2 Role of Prenetics Global Limited in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.13.3 Financials
      • 5.2.13.4 Recent Developments
      • 5.2.13.5 Analyst Perspective
    • 5.2.14 FUJIFILM Holdings Corporation
      • 5.2.14.1 Company Overview
      • 5.2.14.2 Role of FUJIFILM Holdings Corporation in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.14.3 Financials
      • 5.2.14.4 Recent Developments
      • 5.2.14.5 Analyst Perspectives
    • 5.2.15 Olympus Corporation
      • 5.2.15.1 Company Overview
      • 5.2.15.2 Role of Olympus Corporation in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.15.3 Financials
      • 5.2.15.4 Recent Developments
      • 5.2.15.5 Analyst Perspectives
    • 5.2.16 HOYA Corporation
      • 5.2.16.1 Company Overview
      • 5.2.16.2 Role of HOYA Corporation in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.16.3 Financials
      • 5.2.16.4 Analyst Perspectives
    • 5.2.17 QuidelOrtho Corporation
      • 5.2.17.1 Company Overview
      • 5.2.17.2 Role of QuidelOrtho Corporation in the Global Colorectal Cancer Screening and Diagnostic Market
      • 5.2.17.3 Financials
      • 5.2.17.4 Analyst Perspective

List of Figures

  • Figure 1: Global Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 2: Global Colorectal Cancer Screening and Diagnostic Market, Impact Analysis
  • Figure 3: Global Colorectal Cancer Screening and Diagnostic Market (by Type), $Billion 2022 and 2033
  • Figure 4: Global Colorectal Cancer Screening and Diagnostic Market (by End User), $Billion 2022 and 2033
  • Figure 5: Global Colorectal Cancer Screening and Diagnostic Market (by Region), $Billion, 2022 and 2033
  • Figure 6: Global Colorectal Cancer Screening and Diagnostic Market Segmentation
  • Figure 7: Global Colorectal Cancer Screening and Diagnostic Market: Research Methodology
  • Figure 8: Primary Research Methodology
  • Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 10: Top-Down Approach (Segment-Wise Analysis)
  • Figure 11: Global Colorectal Cancer Screening and Diagnostic Market, Patent Analysis (by Country), January 2019-April 2023
  • Figure 12: Global Colorectal Cancer Screening and Diagnostic Market, Patent Analysis (by Year), January 2019-April 2023
  • Figure 13: Stool-Based Molecular Tests, by Company
  • Figure 14: Global Colorectal Cancer Screening and Diagnostic Market, Impact Analysis
  • Figure 15: Number of Colorectal Cancer Cases Globally, 2020- 2040
  • Figure 16: Cancer Survival Rate with Respect to Stage of Detection, 2022
  • Figure 17: Global Colorectal Cancer Screening and Diagnostic Market (by Type)
  • Figure 18: Global Colorectal Cancer Screening and Diagnostic Market, Incremental Opportunity, (by Type), $Billion, 2023-2033
  • Figure 19: Global Colorectal Cancer Screening and Diagnostic Market, Growth-Share Matrix (by Type), 2022-2033
  • Figure 20: Global Colorectal Cancer Screening and Diagnostic Market (Screening), $Billion, 2022-2033
  • Figure 21: Global Colorectal Cancer Screening and Diagnostic Market (Stool-Based Test), $Billion, 2022-2033
  • Figure 22: Global Colorectal Cancer Screening and Diagnostic Market (Fecal Occult Blood Test (FOBT) and Fecal Immunochemical Test (FIT)), $Billion, 2022-2033
  • Figure 23: Global Colorectal Cancer Screening and Diagnostic Market (Stool DNA Test), $Billion, 2022-2033
  • Figure 24: Global Colorectal Cancer Screening and Diagnostic Market (Colonoscopy and Sigmoidoscopy), $Billion, 2022-2033
  • Figure 25: Global Colorectal Cancer Screening and Diagnostic Market (Other Screening Test), $Billion, 2022-2033
  • Figure 26: Global Colorectal Cancer Screening and Diagnostic Market (Diagnostic), $Billion, 2022-2033
  • Figure 27: Global Colorectal Cancer Screening and Diagnostic Market (Biomarker Test), $Billion, 2022-2033
  • Figure 28: Global Colorectal Cancer Screening and Diagnostic Market (Colonoscopy), $Billion, 2022-2033
  • Figure 29: Global Colorectal Cancer Screening and Diagnostic Market (by End User)
  • Figure 30: Global Colorectal Cancer Screening and Diagnostic Market, Incremental Opportunity (by End User), $Billion, 2023-2033
  • Figure 31: Global Colorectal Cancer Screening and Diagnostic Market, Growth-Share Matrix (by End User), 2022-2033
  • Figure 32: Global Colorectal Cancer Screening and Diagnostic Market (Hospitals and Clinics), $Billion, 2022-2033
  • Figure 33: Global Colorectal Cancer Screening and Diagnostic Market (Clinical Laboratories), $Billion, 2022-2033
  • Figure 34: Global Colorectal Cancer Screening and Diagnostic Market (Other End Users), $Billion, 2022-2033
  • Figure 35: Global Colorectal Cancer Screening and Diagnostic Market, %Share (by Region), 2022 and 2033
  • Figure 36: North America Colorectal Cancer Screening, $Billion, 2022-2033
  • Figure 37: North America Colorectal Cancer Screening and Diagnostic Market (by End User), $Billion, 2022-2033
  • Figure 38: North America Colorectal Cancer Screening and Diagnostic Market (by Product), $Billion, 2022-2033
  • Figure 39: North America Colorectal Cancer Screening and Diagnostic Market (by Country), %Share, 2022 and 2033
  • Figure 40: U.S. Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 41: Canada Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 42: Europe Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 43: Europe Colorectal Cancer Screening and Diagnostic Market (by End User), $Billion, 2022-2033
  • Figure 44: Europe Colorectal Cancer Screening and Diagnostic Market (by Product), $Billion, 2022-2033
  • Figure 45: Europe Colorectal Cancer Screening and Diagnostic Market (by Country), Share (%), 2022 and 2033
  • Figure 46: Germany Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 47: U.K. Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 48: France Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 49: Spain Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 50: Italy Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 51: Rest-of-Europe Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 52: Asia-Pacific Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 53: Asia-Pacific Colorectal Cancer Screening and Diagnostic Market (by End User), $Billion, 2022-2033
  • Figure 54: Asia-Pacific Colorectal Cancer Screening and Diagnostic Market (by Product), $Billion, 2022-2033
  • Figure 55: Asia-Pacific Colorectal Cancer Screening and Diagnostic Market (by Country), %Share, 2022 and 2033
  • Figure 56: China Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 57: Japan Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 58: India Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 59: South Korea Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 60: Australia Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 61: Rest-of-Asia-Pacific Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 62: Latin America Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 63: Latin America Colorectal Cancer Screening and Diagnostic Market (by End User), $Billion, 2022-2033
  • Figure 64: Latin America Colorectal Cancer Screening and Diagnostic Market (by Product), $Billion, 2022-2033
  • Figure 65: Latin America Colorectal Cancer Screening and Diagnostic Market (by Country), %Share, 2022 and 2033
  • Figure 66: Brazil Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 67: Mexico Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 68: Rest-of-Latin-America Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 69: Middle East and Africa Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 70: Middle East and Africa Colorectal Cancer Screening and Diagnostic Market (by End User), $Billion, 2022-2033
  • Figure 71: Middle East and Africa Colorectal Cancer Screening and Diagnostic Market (by Product), $Billion, 2022-2033
  • Figure 72: Middle East and Africa Colorectal Cancer Screening and Diagnostic Market (by Country), %Share, 2022 and 2033
  • Figure 73: U.A.E. Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 74: South Africa Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 75: Rest-of-Middle East and Africa Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
  • Figure 76: Global Colorectal Cancer Screening and Diagnostic Market, Number of Key Developments and Strategies, January 2020-April 2023
  • Figure 77: Funding Activities, January 2020-April 2023
  • Figure 78: New Offerings, January 2020-April 2023
  • Figure 79: Business Expansion, January 2020-April 2023
  • Figure 80: Mergers and Acquisitions, January 2020-April 2023
  • Figure 81: Partnerships and Collaborations, January 2020-April 2023
  • Figure 82: Clinical Genomics Technologies Pty Ltd.: Product Portfolio
  • Figure 83: Danaher Corporation: Product Portfolio
  • Figure 84: Danaher Corporation: Overall Financials, $Million, 2020-2022
  • Figure 85: Danaher Corporation: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 86: Danaher Corporation: Net Revenue (by Region), $Million, 2020-2022
  • Figure 87: Danaher Corporation: R&D Expenditure, $Million, 2020-2022
  • Figure 88: DiaCarta, Inc.: Product Portfolio
  • Figure 89: Eiken Chemical Co., Ltd.: Product Portfolio
  • Figure 90: Eiken Chemical Co., Ltd.: Overall Financials, $Million, 2020-2022
  • Figure 91: Epigenomics AG: Product Portfolio
  • Figure 92: Epigenomics AG: Overall Financials, $Million, 2020-2022
  • Figure 93: Epigenomics AG: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 94: Epigenomics AG: Net Revenue (by Region), $Million, 2020-2022
  • Figure 95: Exact Sciences Corporation: Product Portfolio
  • Figure 96: Exact Sciences Corporation: Overall Financials, $Million, 2020-2022
  • Figure 97: Exact Sciences Corporation: Segment Revenues, $Million, 2020-2022
  • Figure 98: Exact Sciences Corporation: Net Revenue (by Region), $Million, 2020-2022
  • Figure 99: Exact Sciences Corporation: R&D Expenditure, $Million, 2020-2022
  • Figure 100: Freenome Holdings, Inc.: Product Portfolio
  • Figure 101: Guardant Health, Inc.: Product Portfolio
  • Figure 102: Guardant Health, Inc.: Overall Financials, $Million, 2020-2022
  • Figure 103: Guardant Health, Inc.: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 104: Guardant Health, Inc.: Net Revenue (by Region), $Million, 2020-2022
  • Figure 105: Guardant Health, Inc.: R&D Expenditure, $Million, 2020-2022
  • Figure 106: Lepu Medical Technology (Beijing) Co., Ltd.: Product Portfolio
  • Figure 107: Lepu Medical Technology (Beijing) Co., Ltd.: Overall Financials, $Million, 2020-2022
  • Figure 108: Mainz Biomed NV: Product Portfolio
  • Figure 109: Mainz Biomed NV: Overall Financials, $Million, 2020-2022
  • Figure 110: New Horizon Health: Product Portfolio
  • Figure 111: New Horizon Health: Overall Financials, $Million, 2020-2022
  • Figure 112: New Horizon Health: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 113: New Horizon Health: Net Revenue (by Region), $Million, 2020-2022
  • Figure 114: Novigenix SA: Product Portfolio
  • Figure 115: Prenetics Global Limited: Product Portfolio
  • Figure 116: Prenetics Global Limited: Overall Financials, $Million, 2021-2022
  • Figure 117: FUJIFILM Holdings Corporation: Product Portfolio
  • Figure 118: FUJIFILM Holdings Corporation: Overall Financials, $Million, 2020-2022
  • Figure 119: FUJIFILM Holdings Corporation: Net Revenue (by Segment), $Million, 2021-2022
  • Figure 120: FUJIFILM Holdings Corporation: R&D Expenditure, $Million, 2020-2022
  • Figure 121: Olympus Corporation: Product Portfolio
  • Figure 122: Olympus Corporation: Overall Financials, $Million, 2020-2022
  • Figure 123: Olympus Corporation: R&D Expenditure, $Million, 2020-2022
  • Figure 124: HOYA Corporation: Product Portfolio
  • Figure 125: HOYA Corporation: Overall Financials, $Million, 2020-2022
  • Figure 126: HOYA Corporation: R&D Expenditure, $Million, 2020-2022
  • Figure 127: QuidelOrtho Corporation: Product Portfolio
  • Figure 128: QuidelOrtho Corporation: Overall Financials, $Million, 2020-2022
  • Figure 129: QuidelOrtho Corporation: Net Revenue (by Segment), $Million, 2020-2022

List of Tables

  • Table 1: Global Colorectal Cancer Screening and Diagnostic Market, Key Developments Analysis, January 2018-April 2023
  • Table 2: Key Questions Answered in the Report
  • Table 3: Global Colorectal Cancer Screening and Diagnostic Market, Product Pipeline
  • Table 4: Examples of Global Colorectal Cancer Screening Initiatives
  • Table 5: Examples of Product Launches and Approval in Asia-Pacific
  • Table 6: North America Colorectal Cancer Screening and Diagnostic Market, Impact Analysis
  • Table 7: Europe Colorectal Cancer Screening and Diagnostic Market, Impact Analysis
  • Table 8: Asia-Pacific Colorectal Cancer Screening and Diagnostic Market, Impact Analysis
  • Table 9: Latin America Colorectal Cancer Screening and Diagnostic Market, Impact Analysis
  • Table 10: Middle East and Africa Colorectal Cancer Screening and Diagnostic Market, Impact Analysis